Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma

European Journal of Cancer

Volumn 50, Issue 3, 2014, Pages 563-569

  Busch, Jonas ^a   Seidel, Christoph ^b   Goranova, Irena ^a   Erber, Barbara ^a   Peters, Robert ^a   Friedersdorff, Frank ^a   Magheli, Ahmed ^a   Miller, Kurt ^a   Grünwald, Viktor ^c   Weikert, Steffen ^a,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d VIVANTES HOSPITAL   (Germany)

Author keywords

Metastasis; Objective response rate; Overall survival; Renal cell carcinoma; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; EVEROLIMUS; LAPATINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TOXICITY; TREATMENT RESPONSE; YOUNG ADULT;

METASTASIS; OBJECTIVE RESPONSE RATE; OVERALL SURVIVAL; RENAL CELL CARCINOMA; TARGETED THERAPY;

AGED; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84893649099     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.10.017     Document Type: Article

References (24)

1. E.J. Mills, B. Rachlis, and C. O'Regan et al. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis BMC Cancer 9 2009 34
2. J.S. Thompson Coon, Z. Liu, and M. Hoyle et al. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness Br J Cancer 101 2 2009 238 243
3. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2 2007 115 124
4. C.N. Sternberg, I.D. Davis, and J. Mardiak et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 6 2010 1061 1068
5. B. Escudier, J. Bellmunt, and S. Negrier et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 13 2010 2144 2150
6. R.J. Motzer, D. Nosov, and T. Eisen et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial ASCO, Meeting Abstracts 30 15-Suppl. 2012 p. 4501
7. R.J. Motzer, B. Escudier, and S. Oudard et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 9637 2008 449 456
8. B.I. Rini, B. Escudier, and P. Tomczak et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 9807 2011 1931 1939
9. C. Seidel, J. Busch, and S. Weikert et al. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma Eur J Cancer 48 7 2012 1023 1030
10. E.J. Abel, S.H. Culp, and N.M. Tannir et al. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib Eur Urol 60 6 2011 1273 1279
11. R.K. Jain, J.J. Lee, and C. Ng et al. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies J Clin Oncol 30 21 2012 2684 2690
12. Molina, A.M., Zhang, J., Lin, X. et al. Sunitinib objective response (OR) in metastatic renal cell carcinoma (mRCC): analysis of 1,059 patients treated on clinical trials. ASCO, Meeting Abstracts 2012; 30(15-suppl): p. 4542.
13. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
14. R.J. Motzer, R.M. Bukowski, and R.A. Figlin et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma Cancer 113 7 2008 1552 1558
15. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 22 2009 3584 3590
16. C.N. Sternberg, R.E. Hawkins, and J. Wagstaff et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update Eur J Cancer 2013
17. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247
18. B. Escudier, T. Eisen, and C. Porta et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 23 Suppl. 7 2012 VIII 65 71
19. A.D. Smith, M.L. Lieber, and S.N. Shah Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT AJR Am J Roentgenol 194 1 2010 157 165
20. A.D. Smith, S.N. Shah, and B.I. Rini et al. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy AJR Am J Roentgenol 194 6 2010 1470 1478
21. J. Busch, C. Seidel, and S. Weikert et al. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma BMC Cancer 11 2011 295
22. J. Busch, C. Seidel, and B. Erber et al. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma Eur Urol 64 1 2013 62 70
23. D.Y. Heng, M.J. Mackenzie, and U.N. Vaishampayan et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy Ann Oncol 23 6 2012 1549 1555
24. D.Y. Heng, W. Xie, and M.M. Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 34 2009 5794 5799